

COMPANY ANNOUNCEMENT
Pharmacare Finance plc (the “Company”)

**Approval of audited financial statements for the
financial year 31 December 2025**

Date of Announcement	23 April 2026
Reference	PHC86/2026
In terms of Chapter 5 of the Capital Markets Rules	

The following is a Company Announcement issued by Pharmacare Finance plc (the “Company”) pursuant to the Capital Markets Rules.

QUOTE

Approval of audited financial statements

The Company announces that the Board of Directors of the Company met on 23 April, 2026 and approved the Company’s Annual Report and Audited Financial Statements for the financial year ended 31 December, 2025. A copy of the Annual Report and Audited Financial Statements for the financial year ended 31 December 2025 are available for viewing and download on the Company’s website: www.pharmacarefinance.com

The Company would also like to announce that the Board of Directors of Pharmacare Premium Limited, being the Guarantor of the EUR17,000,000 6% Unsecured Bonds redeemable in 2033, issued by the Company, also met on 23 April 2026 and approved the Annual Report and Audited Financial Statements for the financial year ended 31 December 2025 of Pharmacare Premium Limited. A copy of the said Annual Report and Audited Financial Statements for the financial year ended 31 December 2025 are also available for viewing and download on the Company’s website: www.pharmacarefinance.com

Explanation of variances in terms of Capital Markets Rule 5.16.24

This announcement is made in accordance with Capital Markets Rule 5.16.24, which requires an explanation of any material difference of ten per cent (10%) or more between actual results and published forecasts, specifically, as at the date hereof, between the forecast contained in the Financial Analysis Summary published by the Company on 29 June, 2025 (the “FAS”) and the abovementioned audited financial statements of each of the Company and the Guarantor for the financial year ended 31 December 2025 (the “Company Accounts” and the “Guarantor Accounts” respectively).

Pharmacare Finance p.l.c.


The financial performance of the Company was largely in line with the forecast set out in the FAS. The pre-tax loss reported in the Company Accounts amounted to €8,912, compared to the break-even (€0) forecast position represented in the FAS. The pre-tax loss of €8,912 was primarily attributable to an increase in administrative overheads.

Pharmacare Premium Limited

The financial performance of the Guarantor was also largely in line with the forecast set out in the FAS. Revenue for the year ended 31 December 2025 amounted to €11,648,934, a decrease of €969,066 compared to the forecast of €12,618,000 in the FAS. Notwithstanding the shortfall in revenue, the pre-tax loss reported in the Guarantor Accounts amounted to €1,990,983, as against the forecast pre-tax loss of approximately €2,237,000 in the FAS. This favourable variance was not attributable to a single line item but rather derived from a combination of improved efficiencies across the Guarantor's operations, resulting in lower direct costs and lower administrative expenses. The EBITDA of the Guarantor amounted to approximately €1,256,000 and outperformed the forecast of approximately €1,101,000 in the FAS by approximately 14%.

UNQUOTE

By order of the Board

A handwritten signature in black ink, appearing to read 'Malcolm Falzon', written over a horizontal line.

Malcolm Falzon
Company Secretary

COMPANY ANNOUNCEMENT**DIRECTORS' DECLARATION
ON ESEF ANNUAL FINANCIAL REPORTS**

We, Amin Farah and Hani H. Sarraf, in our capacity as Directors of Pharmacare Finance p.l.c. (C 86057), hereby certify:

- i. That the Annual Financial Report for the year ended 31 December 2025 has been approved by the Board of Directors of the Company and is hereby being made available to the public.
- ii. That the Annual Financial Report has been prepared in terms of the applicable rules and regulations, including the Commission Delegated Regulation on the European Single Electronic Format ("ESEF")¹ and the Capital Markets Rules²
- iii. That the Audit Report on the ESEF Annual Financial Report is an exact copy of the original signed by the auditor and that no alterations have been made to the audited elements of the Annual Financial Report including the annual financial statements.
- iv. That the Annual Financial Report shall serve as the official document for the purposes of the Capital Markets Rules and the Companies Act (Chapter 386 of the Laws of Malta).



Amin Farah
Director



Hani H. Sarraf
Director

Date: 23 April 2026

¹ Commission Delegated Regulation 2019/815 on the European Single Electronic Format, as may be further amended from time to time.

² Capital Markets Rules as issued by the Malta Financial Services Authority (MFSA).